Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agrima Mian

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Leukemia Research|June 7, 2023
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysisAgrima Mian, Syed Arsalan Ahmed Naqvi, Ahsan Ayaz, et al.
Autopsy & Case Reports|August 24, 2019
Fatal familial hemophagocytic lymphohistiocytosis with perforin gene (<i>PRF1</i>) mutation and EBV-associated T-cell lymphoproliferative disorder of the thyroidAgrima Mian, Kalpana Kumari, Seema Kaushal, et al.
Transplantation and Cellular Therapy|October 1, 2020
Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter AnalysisAdam S Kittai, Ying Huang, Max Gordon, et al.
Heart & Lung : the Journal of Critical Care|October 12, 2020
The association of D-dimers with mortality, intensive care unit admission or acute respiratory distress syndrome in patients hospitalized with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysisAgam Bansal, Achintya D Singh, Vardhmaan Jain, et al.
Leukemia & Lymphoma|December 30, 2020
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysisAgrima Mian, Wei Wei, Allison M Winter, et al.
Bone Marrow Transplantation|February 11, 2023
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucelAgrima Mian, Wei Wei, Betty K Hamilton, et al.
European Journal of Haematology|January 19, 2022
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapseRachel Hu, Wei Wei, Agrima Mian, et al.
American Journal of Hematology|March 25, 2024
BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantationRobert Stuver, Agrima Mian, Samantha Brown, et al.
Transplantation and Cellular Therapy|June 10, 2026
Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapiesAgrima Mian, Rafaella Litvin, Danai Dima, et al.
Blood Advances|February 3, 2023
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Andy Kaempf, Max J Gordon, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Leukemia Research|June 7, 2023
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysisAgrima Mian, Syed Arsalan Ahmed Naqvi, Ahsan Ayaz, et al.
Autopsy & Case Reports|August 24, 2019
Fatal familial hemophagocytic lymphohistiocytosis with perforin gene (<i>PRF1</i>) mutation and EBV-associated T-cell lymphoproliferative disorder of the thyroidAgrima Mian, Kalpana Kumari, Seema Kaushal, et al.
Transplantation and Cellular Therapy|October 1, 2020
Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter AnalysisAdam S Kittai, Ying Huang, Max Gordon, et al.
Heart & Lung : the Journal of Critical Care|October 12, 2020
The association of D-dimers with mortality, intensive care unit admission or acute respiratory distress syndrome in patients hospitalized with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysisAgam Bansal, Achintya D Singh, Vardhmaan Jain, et al.
Leukemia & Lymphoma|December 30, 2020
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysisAgrima Mian, Wei Wei, Allison M Winter, et al.
Bone Marrow Transplantation|February 11, 2023
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucelAgrima Mian, Wei Wei, Betty K Hamilton, et al.
European Journal of Haematology|January 19, 2022
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapseRachel Hu, Wei Wei, Agrima Mian, et al.
American Journal of Hematology|March 25, 2024
BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantationRobert Stuver, Agrima Mian, Samantha Brown, et al.
Transplantation and Cellular Therapy|June 10, 2026
Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapiesAgrima Mian, Rafaella Litvin, Danai Dima, et al.
Blood Advances|February 3, 2023
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Andy Kaempf, Max J Gordon, et al.
Pageof 4